Nofi Michael's most recent trade in SpringWorks Therapeutics Inc was a trade of 78,300 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | Nofi Michael P. | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 78,300 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | P. Nofi Michael | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 65,000 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | P. Michael Nofi | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Nofi Michael P. | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 30,623 | 0 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Michael Nofi P. | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 20,246 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Nofi Michael P. | Chief Accounting Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 8,661 | 0 | - | - | Performance Share Units | |
| SpringWorks Therapeutics Inc | Michael Nofi P. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 20,246 | 20,246 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Nofi P. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 6,929 | 30,623 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Michael Nofi P. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.19 per share. | 04 Jan 2025 | 2,388 | 26,339 (0%) | 0% | 38.2 | 91,198 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi P. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.19 per share. | 04 Jan 2025 | 1,636 | 24,703 (0%) | 0% | 38.2 | 62,479 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi P. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.86 per share. | 04 Jan 2025 | 1,009 | 23,694 (0%) | 0% | 38.9 | 39,210 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 14,104 | 30,959 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Nofi Michael | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.96 per share. | 04 Jan 2024 | 1,169 | 29,790 (0%) | 0% | 38.0 | 44,375 | Common Stock |
| SpringWorks Therapeutics Inc | Nofi Michael | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.53 per share. | 04 Jan 2024 | 1,063 | 28,727 (0%) | 0% | 41.5 | 44,146 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.41 per share. | 07 Jan 2023 | 409 | 16,855 (0%) | 0% | 26.4 | 10,802 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 9,713 | 18,047 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.52 per share. | 05 Jan 2023 | 783 | 17,264 (0%) | 0% | 27.5 | 21,548 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.06 per share. | 07 Jan 2022 | 414 | 8,334 (0%) | 0% | 56.1 | 23,209 | Common Stock |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 17,913 | 17,913 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 5,748 | 8,748 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Michael Nofi | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 3,000 | 3,000 (0%) | 0% | 0 | Common Stock |